Oric Pharmaceuticals Inc 2024年度报告

(MarkOne) ~ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934Forthe fiscal year ended December 31, 2024OR0TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF1934ForthetransitionperiodfromtoCommissionFile Numbe r :001-39269 ORICPHARMACEUTICALS, INC. (ExactnameofRegistrantasspecifiedinits Charter) Indicatebycheckmarkiftheregistrantisa well-known seasoned issuer,asdefmcdinRule405ofthe Securities Act.YES181NO0 Indicatebycheckmarkwhethertheregistrant(I)hasfiled all reportsrequiredtobefiledbySection 13or15(d)ofthe SecuritiesExchangeActof1934 d.uringthepreceding 12months(orfor such shorter period thattheregistrantwasrequired to file such reports),and(2)hasbeensubjecttosuchfiling requirements forthepast90days.YES181NO0 Indicatebycheckmark whether the registrant hassubmittedelectronicallyeveryInteractiveDataFilerequiredtobesubmittedpursuanttoRule405ofRegulationS-T( §232.405ofthis chapter)duringthepreceding 12 months(orforsuch shorter periodthatthe registrantwasrequiredtosubmitsuch files).YES181NOD Indicatebycheckmarkwhetherthe registrantisa large acceleratedfiler,anacceleratedfiler, anon-accelerated filer,smallerreporting company,oranemerginggrowthcompany.Seethedefinitionsof"largeacceleratedfiler,""acceleratedfiler,""smallerreportingcompany,"and"emerginggrowthcompany"in Rule 12b-2oftheExchange Act. Largeaccelerated filerNon-accelerated filer0181Emerginggrowthcompany181 Accelerate d filerSmaller reportingcompany0~ Ifanemerginggrowthcompany, indicatebycheckmarkiftheregistranthaselectednottousctheextended transition period forcomplyingwithanyneworrevised financial accounting standardsprovidedpursuanttoSection 13(a)oftheExchange Act.l8l Indicatebycheckmarkwhetherthe registrant has filed areportonandattestationtoitsmanagement'sassessmentoftheeffectivenessofitsinternal controloverfinancial reportingunderSection 404(b)oftheSarbanes-OxleyAct( 15U.S.C.7262(b))bytheregisteredpublicaccountingfirm thatpreparedorissued itsauditreport.0 If securitiesareregistered pursuanttoSection 12(b)ofthe'Act, indicatebycheck markwhetherthefinancial statementsofthe registrantincluded inthefilingreflectthecorrectionofanerrortopreviously issued financial statements.0 Indicatebycheckmarkwhetheranyofthoseerror correctionsare restatements thatrequireda recovery analysisofincentive-based compensationreceivedbyanyoftheregistrant's executive officersduringthe relevant recovery period pursuantto§240.1OD-1(b) .0 Indicatebycheckmark whether the registrant is ashellcompany(as defmcd in Rule 12b-2oftheExchange Act).YES0 NO181 Theaggregatemarketvalueofthevotingandnon-votingcommonequityheldbynon-affi liatesoftheregistrant, basedontheclosingpriceofthesharesofcommonstockontheNasdaqGlobalSelectMarketonJune30,2024(thelastdayoftheregistrant'smostrecently completedsecondfiscal quarter)was$470.7million.Thenumberofsharesofregistrant' s CommonStockoutstanding asofFebruary 4,2025was71,026,825. Portionsofthe Registrant'sDefinitiveProxyStatement relatingtotheRegistrant'sAnnualMeetingofShareholdersareincorporated by reference intoPartIllofthisAnnual ReportonForm10-Kwhere indicated.SuchDefinitiveProxyStatement willbefiled withtheSecuritiesandExchangeCommissionwithin120daysaftertheendofthe registrant' s2024fiscalyearendedDecember 31, 2024. TableofContents PART I ItemI.Item1A.ItemlB.Item IC.Item 2.Item3.Item4.BusinessRiskFactorsUnresolvedStaffCommentsCybersecurityPropertiesLegalProceedingsMineSafety Disclosures PART II Item 5.Item 6.Item 7.Item7A.Item 8.Item9.Item9A.Item 9B.Item 9C.MarketforRegistrant'sCommonEquity,RelatedStockholderMatters and IssuerPurchasesofEquitySecuritiesReservedManagement'sDiscussion and Analysisoffinancial ConditionandResultsofOperationsQuantitative and Qualitative Disclosures About Market RiskFinancial StatementsandSupplementaryDataChangesinand DisagreementswithAccountantsonAccounting and Financial DisclosureControlsandProceduresOtherInformationDisclosure Regarding Foreign JurisdictionsT hatPrevent Inspections939394101102122122122123 PART IIIItem10. ItemII.Item12.Item 13.Item 14.Directors, Executive Officers and Corporate GovernanceExecutive CompensationSecurityOwnershipofCertainBeneficialOwnersand ManagementandRelatedStockholder MattersCertainRelationships and RelatedTransactions, and Director IndependencePrincipal AccountingFeesand Services124124124124124 PARTlY Item15.Exhibits, Financial Statement SchedulesItem 16Form10-KSummarySIGNATURES This Annual ReportonFormI0-Kcontains. forward-looking statements. All statements other than statementsofhistoricalfacts contained in this Annual ReportonFormI0-K,including statements regarding our future resultsofoperations and financialposition, business strategy, development plans, planned preclinical studies and clinical trials, future resultsofclinical trials, expectedresearch and development costs, regulatory strategy, timing and likelihoodofsuccess, as wellasplans and objectivesofmanagementfor future operations, are forward-looking statement